Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13535458 | 0.87 | MAOB (0.37) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL647871 | 0.86 | IDO1 (0.38) | TSHRIDO1 | |
| SCHEMBL10851642 | 0.83 | MAOB (0.44) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL8750528 | 0.83 | ESR1 (0.42) | ADRA2AADRA2BADRA2CTSHR | |
| SCHEMBL13884107 | 0.83 | MAOB (0.37) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL24331151 | 0.80 | PTPN1 (0.39) | TAAR1MAOBTSHR | |
| SCHEMBL4846046 | 0.80 | MAOB (0.45) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL21518166 | 0.80 | TAAR1 (0.42) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL854787 | 0.80 | TAAR1 (0.38) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL13535461 | 0.79 | KDM4E (0.47) | TAAR1MAOBADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-03-25 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | TAAR1 3330/4885MAOB 3133/4885ADRA2A 4516/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | TAAR1 1023/4885MAOB 4679/4885ADRA2A 315/4885 |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ATM, MAP3K15, MAP3K3 | TAAR1 2233/4885MAOB 3531/4885ADRA2A 2571/4885 |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | TAAR1 4173/4885MAOB 3631/4885ADRA2A 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.